Clinilabs, a CRO that provides early-stage and clinical drug development services to industry, has been selected to conduct a phase I clinical research study of an investigational medication in patients with Obstructive Sleep Apnea (OSA).

Barbara Smallwood, vice president of business development, states “We are proud to continue our part in the search for new and innovative treatments for sleep disorders, and we look forward to assessing the effects of an investigational new drug on patients with OSA.”